A Study in Healthy Men to Test How BI 764198 is Processed in the Body
Phase 1
Completed
NCT05863130
| Condition | Healthy |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Boehringer Ingelheim |
|---|
| Status | Completed |
|---|
| Enrollment | 24 participants |
|---|
| Interventions | BI 764198 (C-14) (approach 1), BI 764198 (C-14) (approach 2) |
|---|
| Start date | May 3, 2023 |
|---|
| Completion date | Nov 9, 2023 |
|---|
| Results posted | Jun 3, 2026 |
|---|
Summary
The main objective of this trial is to investigate the basic pharmacokinetics of BI 764198 and its metabolites, total radioactivity including mass balance, excretion pathways and metabolism following oral administration to healthy male volunteers of a single oral dose of BI 764198 (C-14) in i) a classical hADME approach and ii) a hADME microtracer approach.
Mass Balance Recovery of Total Radioactivity in Urine and Faeces: Amount Excreted Within the Time Interval From 0 to the Time of the Last Quantifiable Data Point as a Percentage of the Administered Dose (fe0-tz) for Urine and Faeces.
Urine and feces sample collection: 48 hours before and up to 725 hours after drug administration. The details are mentioned in the description section. · Percentage of dose excreted
| Cohort 1: Classical hADME | 73.7 ± 6.23 Percentage of dose excreted |
|---|
| Cohort 2: Microtracer hADME | 73.2 ± 6.04 Percentage of dose excreted |
|---|
| Cohort 1: Classical hADME | 22.9 ± 10.7 Percentage of dose excreted |
|---|
| Cohort 2: Microtracer hADME | 22.4 ± 10.6 Percentage of dose excreted |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.